Investment in technology is driving the digital transformation of pharma and biotech business operations in key areas such as drug discovery, clinical trials and manufacturing. As companies become more dependent on technology, successfully procuring and integrating advanced applications will be a top priority for decision-makers, but without the right guidance they risk wasting a lot of resources. 

Developing a new drug is a costly and uncertain process. Pharma and biotech firms are taking steps to reduce the lengthy pathway to approval and cut costs throughout the value chain with digital technologies such as AI, which is upending the drug discovery pipeline; big data and analytics tools, which are being used in clinical trials to support drug development and deliver new treatments and diagnostics processes; and blockchain, which is improving track and trace.  

This webinar – hosted by the Financial Times in partnership with Infosys – will explore how pharma and biotech firms are attempting to unlock efficiencies by digitising, simplifying and connecting systems, processes and data. It will look at how they are overcoming hurdles, such as investing in new and emerging skills, finding new partners, and reshaping internal practices to develop a digital-first mindset. It will also evaluate how to create a strategic road map for a successful transformation process.  

Understand

The big picture, not just the individual strands of the business you work in

Connect

And build relationships with some of the biggest names in your industry

Discover

New approaches and strategies to help win market share

Premier Digital Events Supported by the World's Best Journalism

Using leading digital technology, we have now taken our content, global audience reach and engagement to a new level through a series of unmissable virtual events. Our compelling events are chaired by respected FT journalists, feature the most senior and thought-provoking decision-makers in business, finance and politics, all accessible from your office or home.

© Financial Times Live

FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice